 | • レポートコード：MRC2304F024 • 出版社/出版日：360iResearch / 2022年10月 • レポート形態：英語、PDF、232ページ • 納品方法：Eメール（受注後2-3日） • 産業分類：医薬品 |
| Single User（1名利用、印刷可） | ￥742,350 (USD4,949) | ▷ お問い合わせ |
| Enterprise License（企業利用、印刷可） | ￥1,492,350 (USD9,949) | ▷ お問い合わせ |
• お支払方法：銀行振込（納品後、ご請求書送付）
レポート概要
| 360iResearch社の本市場調査資料では、世界の動物用ワクチン市場規模が、2021年に140.0億ドル、2022年に151.4億ドルになり、その後CAGR 8.29％で成長して2027年までに225.9億ドルに達すると予測しています。本書は、動物用ワクチンの世界市場を対象とした調査・分析結果をまとめたものであり、序論、調査方法、エグゼクティブサマリー、市場概要、市場インサイト、製品別分析（弱毒生ワクチン、DNAワクチン、不活化ワクチン、組換えワクチン、サブユニットワクチン）、動物種類別分析（水生動物、伴侶動物、家禽、反芻動物）、地域別分析（南北アメリカ、アメリカ、カナダ、ブラジル、アジア太平洋、日本、中国、インド、韓国、台湾、ヨーロッパ/中東/アフリカ、イギリス、ドイツ、フランス、ロシア、その他）、競争状況、企業情報などの内容を掲載しています。なお、本書内の企業情報には、Anicon Labor GmbH by SNA group、Biogénesis Bagó S.A.、Boehringer Ingelheim International GmbH、Brilliant Bio Pharma Private limited、Ceva Santé Animale、China Animal Husbandry Industry Co., Ltd.、Elanco LLC、Endovac Animal Health, LLCなどが含まれています。 ・序論 ・調査方法 ・エグゼクティブサマリー ・市場概要 ・市場インサイト ・世界の動物用ワクチン市場規模：製品別 - 弱毒生ワクチンの市場規模 - DNAワクチンの市場規模 - 不活化ワクチンの市場規模 - 組換えワクチンの市場規模 - サブユニットワクチンの市場規模 ・世界の動物用ワクチン市場規模：動物種類別 - 水生動物における市場規模 - 伴侶動物における市場規模 - 家禽における市場規模 - 反芻動物における市場規模 ・世界の動物用ワクチン市場規模：地域別 - 南北アメリカの動物用ワクチン市場規模 アメリカの動物用ワクチン市場規模 カナダの動物用ワクチン市場規模 ブラジルの動物用ワクチン市場規模 ... - アジア太平洋の動物用ワクチン市場規模 日本の動物用ワクチン市場規模 中国の動物用ワクチン市場規模 インドの動物用ワクチン市場規模 韓国の動物用ワクチン市場規模 台湾の動物用ワクチン市場規模 ... - ヨーロッパ/中東/アフリカの動物用ワクチン市場規模 イギリスの動物用ワクチン市場規模 ドイツの動物用ワクチン市場規模 フランスの動物用ワクチン市場規模 ロシアの動物用ワクチン市場規模 ... - その他地域の動物用ワクチン市場規模 ・競争状況 ・企業情報 |
The Global Animal Vaccines Market size was estimated at USD 14.00 billion in 2021 and expected to reach USD 15.14 billion in 2022, and is projected to grow at a CAGR 8.29% to reach USD 22.59 billion by 2027.
Market Statistics:
The report provides market sizing and forecast across 7 major currencies – USD, EUR, JPY, GBP, AUD, CAD, and CHF. It helps organization leaders make better decisions when currency exchange data is readily available. In this report, the years 2018 and 2020 are considered as historical years, 2021 as the base year, 2022 as the estimated year, and years from 2023 to 2027 are considered as the forecast period.
Market Segmentation & Coverage:
This research report categorizes the Animal Vaccines to forecast the revenues and analyze the trends in each of the following sub-markets:
Based on Product, the market was studied across Attenuated Live Vaccines, DNA Vaccines, Inactivated Vaccines, Recombinant Vaccines, and Subunit Vaccines.
Based on Animal Type, the market was studied across Aqua, Companion, Poultry, and Ruminants. The Aqua is further studied across Aeromonas, Streptococcosis, and Vibrio. The Companion is further studied across Canine and Feline. The Canine is further studied across Canine Herpes, Distemper, Kennel Cough, Lyme Disease, Parvovirus, and Rabies Canine. The Feline is further studied across Calicivirus, Coronavirus Feline, Panleukopenia, Rabies Feline, and Rhinotracheitis. The Poultry is further studied across Avian Influenza, Infectious Bronchitis, Marek’s Disease, Newcastle Disease, and Salmonella. The Ruminants is further studied across Coronavirus Ruminants, E. Coli, Foot & mouth disease (FMD), Lumpy skin, and Rotavirus.
Based on Region, the market was studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.
Cumulative Impact of COVID-19:
COVID-19 is an incomparable global public health emergency that has affected almost every industry, and the long-term effects are projected to impact the industry growth during the forecast period. Our ongoing research amplifies our research framework to ensure the inclusion of underlying COVID-19 issues and potential paths forward. The report delivers insights on COVID-19 considering the changes in consumer behavior and demand, purchasing patterns, re-routing of the supply chain, dynamics of current market forces, and the significant interventions of governments. The updated study provides insights, analysis, estimations, and forecasts, considering the COVID-19 impact on the market.
Cumulative Impact of 2022 Russia Ukraine Conflict:
We continuously monitor and update reports on political and economic uncertainty due to the Russian invasion of Ukraine. Negative impacts are significantly foreseen globally, especially across Eastern Europe, European Union, Eastern & Central Asia, and the United States. This contention has severely affected lives and livelihoods and represents far-reaching disruptions in trade dynamics. The potential effects of ongoing war and uncertainty in Eastern Europe are expected to have an adverse impact on the world economy, with especially long-term harsh effects on Russia.This report uncovers the impact of demand & supply, pricing variants, strategic uptake of vendors, and recommendations for Animal Vaccines market considering the current update on the conflict and its global response.
Competitive Strategic Window:
The Competitive Strategic Window analyses the competitive landscape in terms of markets, applications, and geographies to help the vendor define an alignment or fit between their capabilities and opportunities for future growth prospects. It describes the optimal or favorable fit for the vendors to adopt successive merger and acquisition strategies, geography expansion, research & development, and new product introduction strategies to execute further business expansion and growth during a forecast period.
FPNV Positioning Matrix:
The FPNV Positioning Matrix evaluates and categorizes the vendors in the Animal Vaccines Market based on Business Strategy (Business Growth, Industry Coverage, Financial Viability, and Channel Support) and Product Satisfaction (Value for Money, Ease of Use, Product Features, and Customer Support) that aids businesses in better decision making and understanding the competitive landscape.
Market Share Analysis:
The Market Share Analysis offers the analysis of vendors considering their contribution to the overall market. It provides the idea of its revenue generation into the overall market compared to other vendors in the space. It provides insights into how vendors are performing in terms of revenue generation and customer base compared to others. Knowing market share offers an idea of the size and competitiveness of the vendors for the base year. It reveals the market characteristics in terms of accumulation, fragmentation, dominance, and amalgamation traits.
Competitive Scenario:
The Competitive Scenario provides an outlook analysis of the various business growth strategies adopted by the vendors. The news covered in this section deliver valuable thoughts at the different stage while keeping up-to-date with the business and engage stakeholders in the economic debate. The competitive scenario represents press releases or news of the companies categorized into Merger & Acquisition, Agreement, Collaboration, & Partnership, New Product Launch & Enhancement, Investment & Funding, and Award, Recognition, & Expansion. All the news collected help vendor to understand the gaps in the marketplace and competitor’s strength and weakness thereby, providing insights to enhance product and service.
Company Usability Profiles:
The report profoundly explores the recent significant developments by the leading vendors and innovation profiles in the Global Animal Vaccines Market, including Anicon Labor GmbH by SNA group, Biogénesis Bagó S.A., Boehringer Ingelheim International GmbH, Brilliant Bio Pharma Private limited, Ceva Santé Animale, China Animal Husbandry Industry Co., Ltd., Elanco LLC, Endovac Animal Health, LLC, Heska Corporation, Hester Biosciences Limited, HIPRA, S.A., Indian Immunologicals Limited, Merck KGaA, Neogen Corporation, Phibro Animal Health Corporation, Sanofi S.A., Torigen Pharmaceuticals Inc., Vaxxinova GmbH, VEROVACCiNES GmbH, Vetoquinol SA, Virbac, Inc., and Zoetis Inc..
The report provides insights on the following pointers:
1. Market Penetration: Provides comprehensive information on the market offered by the key players
2. Market Development: Provides in-depth information about lucrative emerging markets and analyze penetration across mature segments of the markets
3. Market Diversification: Provides detailed information about new product launches, untapped geographies, recent developments, and investments
4. Competitive Assessment & Intelligence: Provides an exhaustive assessment of market shares, strategies, products, certification, regulatory approvals, patent landscape, and manufacturing capabilities of the leading players
5. Product Development & Innovation: Provides intelligent insights on future technologies, R&D activities, and breakthrough product developments
The report answers questions such as:
1. What is the market size and forecast of the Global Animal Vaccines Market?
2. What are the inhibiting factors and impact of COVID-19 shaping the Global Animal Vaccines Market during the forecast period?
3. Which are the products/segments/applications/areas to invest in over the forecast period in the Global Animal Vaccines Market?
4. What is the competitive strategic window for opportunities in the Global Animal Vaccines Market?
5. What are the technology trends and regulatory frameworks in the Global Animal Vaccines Market?
6. What is the market share of the leading vendors in the Global Animal Vaccines Market?
7. What modes and strategic moves are considered suitable for entering the Global Animal Vaccines Market?
1. Preface
1.1. Objectives of the Study
1.2. Market Segmentation & Coverage
1.3. Years Considered for the Study
1.4. Currency & Pricing
1.5. Language
1.6. Limitations
1.7. Assumptions
1.8. Stakeholders
2. Research Methodology
2.1. Define: Research Objective
2.2. Determine: Research Design
2.3. Prepare: Research Instrument
2.4. Collect: Data Source
2.5. Analyze: Data Interpretation
2.6. Formulate: Data Verification
2.7. Publish: Research Report
2.8. Repeat: Report Update
3. Executive Summary
4. Market Overview
5. Market Insights
5.1. Market Dynamics
5.1.1. Drivers
5.1.1.1. Growing Livestock Population
5.1.1.2. Rising Animal Husbandry along with Commercialization of Animal Products
5.1.1.3. Increasing Incidences of Zoonotic Diseases
5.1.2. Restraints
5.1.2.1. Supply End Costs are Relatively High, with Poorer Capital Returns than Human Vaccines
5.1.3. Opportunities
5.1.3.1. Shift from Live Attenuated Vaccines to DNA Vaccines
5.1.3.2. Continuous Technological Advancements in Vaccines
5.1.4. Challenges
5.1.4.1. Adverse Impacts of Vaccines
5.2. Cumulative Impact of COVID-19
6. Animal Vaccines Market, by Product
6.1. Introduction
6.2. Attenuated Live Vaccines
6.3. DNA Vaccines
6.4. Inactivated Vaccines
6.5. Recombinant Vaccines
6.6. Subunit Vaccines
7. Animal Vaccines Market, by Animal Type
7.1. Introduction
7.2. Aqua
7.3.1. Aeromonas
7.3.2. Streptococcosis
7.3.3. Vibrio
7.3. Companion
7.4.1. Canine
7.4.2.1. Canine Herpes
7.4.2.2. Distemper
7.4.2.3. Kennel Cough
7.4.2.4. Lyme Disease
7.4.2.5. Parvovirus
7.4.2.6. Rabies Canine
7.4.2. Feline
7.4.3.1. Calicivirus
7.4.3.2. Coronavirus Feline
7.4.3.3. Panleukopenia
7.4.3.4. Rabies Feline
7.4.3.5. Rhinotracheitis
7.4. Poultry
7.5.1. Avian Influenza
7.5.2. Infectious Bronchitis
7.5.3. Marek’s Disease
7.5.4. Newcastle Disease
7.5.5. Salmonella
7.5. Ruminants
7.6.1. Coronavirus Ruminants
7.6.2. E. Coli
7.6.3. Foot & mouth disease (FMD)
7.6.4. Lumpy skin
7.6.5. Rotavirus
8. Americas Animal Vaccines Market
8.1. Introduction
8.2. Argentina
8.3. Brazil
8.4. Canada
8.5. Mexico
8.6. United States
9. Asia-Pacific Animal Vaccines Market
9.1. Introduction
9.2. Australia
9.3. China
9.4. India
9.5. Indonesia
9.6. Japan
9.7. Malaysia
9.8. Philippines
9.9. Singapore
9.10. South Korea
9.11. Taiwan
9.12. Thailand
9.13. Vietnam
10. Europe, Middle East & Africa Animal Vaccines Market
10.1. Introduction
10.2. Denmark
10.3. Egypt
10.4. Finland
10.5. France
10.6. Germany
10.7. Israel
10.8. Italy
10.9. Netherlands
10.10. Nigeria
10.11. Norway
10.12. Poland
10.13. Qatar
10.14. Russia
10.15. Saudi Arabia
10.16. South Africa
10.17. Spain
10.18. Sweden
10.19. Switzerland
10.20. Turkey
10.21. United Arab Emirates
10.22. United Kingdom
11. Competitive Landscape
11.1. FPNV Positioning Matrix
11.1.1. Quadrants
11.1.2. Business Strategy
11.1.3. Product Satisfaction
11.2. Market Ranking Analysis, By Key Player
11.3. Market Share Analysis, By Key Player
11.4. Competitive Scenario
11.4.1. Merger & Acquisition
11.4.2. Agreement, Collaboration, & Partnership
11.4.3. New Product Launch & Enhancement
11.4.4. Investment & Funding
11.4.5. Award, Recognition, & Expansion
12. Company Usability Profiles
12.1. Anicon Labor GmbH by SNA group
12.1.1. Business Overview
12.1.2. Key Executives
12.1.3. Product & Services
12.2. Biogénesis Bagó S.A.
12.2.1. Business Overview
12.2.2. Key Executives
12.2.3. Product & Services
12.3. Boehringer Ingelheim International GmbH
12.3.1. Business Overview
12.3.2. Key Executives
12.3.3. Product & Services
12.4. Brilliant Bio Pharma Private limited
12.4.1. Business Overview
12.4.2. Key Executives
12.4.3. Product & Services
12.5. Ceva Santé Animale
12.5.1. Business Overview
12.5.2. Key Executives
12.5.3. Product & Services
12.6. China Animal Husbandry Industry Co., Ltd.
12.6.1. Business Overview
12.6.2. Key Executives
12.6.3. Product & Services
12.7. Elanco LLC
12.7.1. Business Overview
12.7.2. Key Executives
12.7.3. Product & Services
12.8. Endovac Animal Health, LLC
12.8.1. Business Overview
12.8.2. Key Executives
12.8.3. Product & Services
12.9. Heska Corporation
12.9.1. Business Overview
12.9.2. Key Executives
12.9.3. Product & Services
12.10. Hester Biosciences Limited
12.10.1. Business Overview
12.10.2. Key Executives
12.10.3. Product & Services
12.11. HIPRA, S.A.
12.11.1. Business Overview
12.11.2. Key Executives
12.11.3. Product & Services
12.12. Indian Immunologicals Limited
12.12.1. Business Overview
12.12.2. Key Executives
12.12.3. Product & Services
12.13. Merck KGaA
12.13.1. Business Overview
12.13.2. Key Executives
12.13.3. Product & Services
12.14. Neogen Corporation
12.14.1. Business Overview
12.14.2. Key Executives
12.14.3. Product & Services
12.15. Phibro Animal Health Corporation
12.15.1. Business Overview
12.15.2. Key Executives
12.15.3. Product & Services
12.16. Sanofi S.A.
12.16.1. Business Overview
12.16.2. Key Executives
12.16.3. Product & Services
12.17. Torigen Pharmaceuticals Inc.
12.17.1. Business Overview
12.17.2. Key Executives
12.17.3. Product & Services
12.18. Vaxxinova GmbH
12.18.1. Business Overview
12.18.2. Key Executives
12.18.3. Product & Services
12.19. VEROVACCiNES GmbH
12.19.1. Business Overview
12.19.2. Key Executives
12.19.3. Product & Services
12.20. Vetoquinol SA
12.20.1. Business Overview
12.20.2. Key Executives
12.20.3. Product & Services
12.21. Virbac, Inc.
12.21.1. Business Overview
12.21.2. Key Executives
12.21.3. Product & Services
12.22. Zoetis Inc.
12.22.1. Business Overview
12.22.2. Key Executives
12.22.3. Product & Services
13. Appendix
13.1. Discussion Guide
13.2. License & Pricing